Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SmithKline OTC sales jump 68% in second quarter with Panadol contribution.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE BEECHAM OTC SALES JUMP 68% IN SECOND QUARTER boosted by the contribution of Sterling Winthrop's international OTC business led by Panadol. SmithKline Beecham's OTC sales for the quarter were [pound]254 mil., or $403.8 mil., based on the currency translation of [pound]=$1.59. The company noted in a July 25 release that the inclusion of the Sterling products led to a 41% sales gain in Europe and 118% sales growth in international markets

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS084127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel